title: General practitioners' adoption of new drugs and previous prescribing of drugs belonging to the same therapeutic class: a pharmacoepidemiological study.
abstract: OBJECTIVE
  To test the hypothesis that general practitioners (GPs) with high prescribing levels of certain drugs will adopt new drugs belonging to the same therapeutic group faster than those with low prescribing levels.
  
  
  METHODS
  The adoption of four new drugs: esomeprazol, selective cyclo-oxygenase-2 inhibitors, new triptans, and angiotensin-II receptor blockers were analysed using population-based prescription data. We used the preference proportion (prescriptions for new rather than older alternatives for the same indication) to measure GPs' adoption rate. Annual prescribing volume and prevalence were used to measure previous prescribing of older drug alternatives. We modelled the preference proportion using multiple linear regression analysis and the prescribing of older drugs as independent variables. We controlled for the GPs' general prescribing level and weighted for practice size. In the first three analyses, we dichotomized data using the median, lower and upper quartile as cut-off point. Next, we grouped data into quartiles and finally, we used continuous data.
  
  
  RESULTS
  For esomeprazol and new triptans there was a higher preference for new drugs among "high prescribers", but only when this term was defined as the upper quarter and the upper half of previous prescribing levels, respectively (mean difference in preference proportion: 10.2% (99% confidence interval = 1.3%, 19.1%) and 8.2% (0.2%, 16.2%)). For the remaining two drug classes the associations were weak and almost all statistically nonsignificant.
  
  
  CONCLUSIONS
  There is no consistent association between GPs' level of drug prescribing and their adoption of new drugs of the same therapeutic group.
authors.affiliation: Research Unit of General Practice, Institute of Public Health, University of Southern Denmark, J.B. Winsløws Vej. 9, DK-5000 Odense, Denmark.
authors.forename: Torben
authors.initials: T
authors.lastname: Dybdahl
authors.forename: Morten
authors.initials: M
authors.lastname: Andersen
authors.forename: Jakob
authors.initials: J
authors.lastname: Kragstrup
authors.forename: Ivar Sønbø
authors.initials: IS
authors.lastname: Kristiansen
authors.forename: Jens
authors.initials: J
authors.lastname: Søndergaard
mesh_terms: D000328:Adult; D000368:Aged; D057911:Angiotensin Receptor Antagonists; D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D001291:Attitude of Health Personnel; D003258:Consumer Behavior; D052246:Cyclooxygenase 2 Inhibitors / Q000627:therapeutic use; D003718:Denmark; D004059:Diffusion of Innovation; D004363:Drug Utilization; D005194:Family Practice / Q000639:trends*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000627:therapeutic use; D010818:Practice Patterns, Physicians' / Q000639:trends*; D012044:Regression Analysis; D014363:Tryptamines / Q000627:therapeutic use
chemical_list: D057911:Angiotensin Receptor Antagonists; D000897:Anti-Ulcer Agents; D052246:Cyclooxygenase 2 Inhibitors; D014363:Tryptamines; D009853:Omeprazole